Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England

Kuo, Chang-Fu; Grainge, Matthew J.; Mallen, Christian; Zhang, Weiya; Doherty, Michael

Abstract

Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription.

Citation

Kuo, C., Grainge, M. J., Mallen, C., Zhang, W., & Doherty, M. (2014). Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. Journal of the American Medical Association, 312(24), https://doi.org/10.1001/jama.2014.14484

• Journal Article Type: Article
• Acceptance Date: Aug 12, 2014
• Publication Date: Dec 24, 2014
• Deposit Date: Aug 18, 2016
• Journal: Journal of the American Medical Association
• Print ISSN: 0098-7484
• Electronic ISSN: 0098-7484
• Publisher: American Medical Association
• Peer Reviewed: Peer Reviewed
• Volume: 312
• Issue: 24
• DOI: https://doi.org/10.1001/jama.2014.14484
• Public URL: https://nottingham-repository.worktribe.com/output/740521
• Publisher URL: http://jama.jamanetwork.com/article.aspx?articleid=2084879